CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever …

CSL was established in Australia in 1916. Over the ensuing years, CSL provided Australians with rapid access to 20th century medical advances including insulin and penicillin, and vaccines against …

Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides …

Our parent company, CSL, headquartered in Melbourne, Australia, employs more than 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.

CSL is committed to protecting public health and improving and saving the lives of patients with rare and serious diseases through the development, manufacture and reliable supply of high-quality medicines.

Recent News Releases Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Biotech leader CSL has manufacturing centers, sales offices, and locations to serve patients and public health around the globe.

CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with nearly 330 plasma donation centers globally, including the U.S. and Europe and employs nearly …

Investment in R&D is an important driver for CSL’s future growth. New and exciting opportunities allow us to address previously unmet patient needs and these continue to drive us each day.

Jun 30, 2025 · Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis.